Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

2026 CSCCP-ASCCP Colposcopy Training Course--Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions


News provided by

Asieris

Oct 23, 2026, 02:03 ET

Share this article

Share toX

Share this article

Share toX

  • Advancing Precision Diagnosis and Treatment
  • Photodynamic Therapy Introduced for the First Time into Colposcopy Faculty Training in China

WUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded successfully. Jointly organized by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) and the American Society for Colposcopy and Cervical Pathology (ASCCP), and co-hosted by Tongji Hospital and Union Hospital, both affiliated with Tongji Medical College of Huazhong University of Science and Technology, the program featured live demonstrations and teaching sessions on representative clinical cases, lectures on foundational principles and the latest advances, interdisciplinary clinical-pathological discussions, and multidisciplinary team (MDT) consultations on challenging cases. Emphasizing precision diagnosis, treatment, and risk-stratified management, the program also marked the first time photodynamic therapy (PDT) had been incorporated into colposcopy faculty training in China, with the PDT training sessions supported by Asieris Pharmaceuticals. This initiative represents a practical contribution to China's efforts to foster a fertility-friendly society and advance the management of cervical lesions toward greater precision and non-invasive treatment.

Continue Reading
2026 CSCCP-ASCCP Colposcopy Training Course—Wuhan Station
2026 CSCCP-ASCCP Colposcopy Training Course—Wuhan Station

During the three-day program, more than 60 clinicians specializing in colposcopy and the diagnosis and treatment of cervical lesions from across China completed systematic training and the final examination. The program was conducted under the honorary chairmanship of Professor Ding Ma, Member of the Chinese Academy of Engineering and Chair of the Department of Obstetrics and Gynecology at Tongji Hospital. Professor Peng Wu, Director of the Department of Obstetrics and Gynecology at Union Hospital, served as program lead. Professor Nan Yu, Head of the Cervical Disease Specialty at Tongji Hospital, and Professor Rui Gao of Union Hospital served as course coordinators.

The faculty also included Professor Christine Conageski of the University of Colorado; Professor Chenquan Zhao, University of Pittsburgh Medical Center and Chief Overseas Medical Advisor to CSCCP; Professor Yuxin Liu of the Department of Pathology at the Icahn School of Medicine at Mount Sinai; and Professor Francisco García, Member of the U.S. National Academy of Medicine and former President of ASCCP, among other experts.

Precision Diagnosis and Risk-Stratified Management Throughout the Training Program

The principles of precision diagnosis, treatment, and risk-stratified management were integrated into every component of the program, from procedural demonstrations and theoretical lectures to case-based discussions. During live demonstrations of colposcopy, loop electrosurgical excision procedure (LEEP), laser ablation, and PDT, experts presented cases representing different risk levels, incorporating risk-based decision-making throughout colposcopic assessment, biopsy sampling, and individualized treatment planning.

The didactic sessions covered a comprehensive range of clinical topics. Chinese and U.S. experts discussed triage and management of individuals who test positive for HPV during primary screening; HPV integration empowers precision diagnosis and treatment of cervical lesions; advances in the pathological diagnosis of cervical cancer and precancerous lesions; colposcopy techniques and quality control; standardized colposcopy terminology and reporting; treatment strategies for cervical intraepithelial neoplasia grade 2 (CIN2) based on the latest 2026 U.S. National Cancer Institute data; the development and clinical translation of the world's first trivalent HPV therapeutic vaccine; risk-based colposcopy management; management of positive surgical margins following cervical conization; diagnostic pitfalls in cervical biopsy pathology; colposcopy and fertility preservation in lower genital tract and cervical diseases; the colposcopic identification of cervical glandular lesions; and the diagnosis and treatment of vaginal intraepithelial neoplasia with case sharing; interpretation of the 2026 ISSVD terminology standards for vulvar intraepithelial neoplasia and squamous intraepithelial lesions; and the diagnosis and management of vulvar lichenoid diseases.

From triage following a positive primary HPV screening result to quality assurance in colposcopy, standardized reporting, and the management of positive surgical margins, the program promoted an integrated approach spanning the entire care pathway: screening, triage, diagnosis, treatment, and follow-up.

During the interdisciplinary clinical-pathological and MDT case discussions, Chinese and international experts guided participants through case reviews incorporating pathological findings. In-depth discussions addressed key diagnostic challenges, including concordance between colposcopic impressions and pathological diagnoses, as well as potential pitfalls in cervical biopsy interpretation. These sessions helped participants strengthen their ability to integrate clinical, pathological, and molecular information to support more precise clinical decision-making.

Several participating clinicians noted that this risk-stratified approach to faculty training offered practical guidance for standardizing colposcopy practice, particularly in primary and community-level healthcare settings.

PDT Incorporated into Colposcopy Faculty Training in China for the First Time, Supporting Standardized Non-Invasive Treatment

Another highlight of the program was the first-ever inclusion of PDT in a colposcopy faculty training program in China, with a dedicated curriculum combining theoretical instruction and simulated hands-on practice.

As cervical precancerous lesions are increasingly being diagnosed in younger women, an important clinical challenge is how to effectively treat these lesions while preserving reproductive function in women of childbearing age. Traditional excisional treatments can effectively remove lesions but may increase the risks of adverse pregnancy outcomes, including miscarriage and preterm birth, as well as cervical stenosis.

PDT is a non-excisional, non-invasive treatment approach that uses light-activated photosensitizers to selectively target abnormal cells. It can also help eliminate high-risk human papillomavirus (HPV), offering a treatment option that aims to control lesions while preserving normal cervical anatomy and function. This approach may be particularly relevant for women who wish to preserve their fertility.

PDT has been recommended in relevant expert consensus documents, and a portable cervical PDT technology has been approved in China for the treatment of CIN2. It may be particularly suitable for women who plan to conceive in the near future or who wish to preserve their future reproductive options, subject to individualized clinical assessment.

During the training, experts provided live demonstrations of LEEP, laser ablation, and PDT, enabling participants to observe procedural workflows and the considerations involved in selecting appropriate patients. The curriculum also included sessions on procedural principles and simulated practice in colposcopy, LEEP, laser ablation, and PDT. Under expert supervision, participants practiced the relevant procedures and learned the standardized operating protocols, principles of efficacy assessment, and key considerations for post-treatment follow-up associated with PDT.

A dedicated lecture on colposcopy for lower genital tract and cervical diseases, with a focus on fertility preservation, further reinforced the importance of fertility-conscious clinical decision-making.

The inclusion of PDT in colposcopy faculty training represents a step toward equipping clinicians not only with standardized diagnostic skills but also with training in non-invasive treatment options. By strengthening clinical capabilities across both diagnosis and treatment, the program supports more comprehensive management of cervical lesions while contributing to China's broader efforts to build a fertility-friendly society.

From advancing risk-stratified precision management to pioneering the inclusion of PDT in colposcopy faculty training in China, 2026 CSCCP-ASCCP Colposcopy Training Course—Wuhan Station represented more than a systematic effort to strengthen clinical teaching capabilities. It also marked an important practical step toward more precise, individualized, and non-invasive management of cervical lesions.

SOURCE Asieris

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative therapies for...

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Education

Education

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content

About

  • About PR Newswire
  • About Cision
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.